Open AccessIsolation of Circulating Tumor Cells to Diagnose Melanoma and Evaluate the Efficacy of Surgical Resection Using Melanoma‐Specific Microsystem
Author(s) -
Kang Yoon-Tae,
Mutukuri Anusha,
Hadlock Thomas,
Fairbairn Heather,
Carle Taylor R.,
Fouladdel Shamileh,
Murlidhar Vasudha,
Kramer Aaron,
Reguera Monica De Silva,
Azizi Ebrahim,
Durham Alison,
Mclean Scott A.,
Nagrath Sunitha
Publication year - 2022
Publication title -
advanced nanobiomed research
Language(s) - English
Resource type - Journals
ISSN - 2699-9307
DOI - 10.1002/anbr.202100083
Subject(s) - melanoma , circulating tumor cell , medicine , liquid biopsy , biopsy , metastasis , cancer , cancer research , pathology , oncology
Melanoma is one of the most aggressive skin cancers due to its potential to metastasize widely in the body. The risk of metastasis is increased with later detection and increased thickness of the primary lesion, thus early identification/surgical removal is critical for higher survival rates. Recent advances in liquid biopsy have proposed less‐invasive alternatives for cancer diagnosis and monitoring using minimal invasion at sample collection, and circulating tumor cells (CTCs) have been considered a promising blood‐based surrogate marker of primary tumors. Herein, the melanoma‐specific OncoBean platform (MelanoBean) conjugated with melanoma specific antibodies is used. From the comprehensive studies based on change in the number and characteristics of CTCs/CTCs‐clusters pre‐ and post‐surgical treatment, this work demonstrates that melanoma patients ( n = 45) at all stages (I–IV) have a noticeable number of CTCs as well as CTC‐clusters compared to healthy donors ( n = 9) ( p = 0.0011), and surgical treatment leads to a significant decrease in the CTC number ( p < 0.0001). The CTCs recovered from the device undergo molecular profiling for melanoma‐associated genes expression using multiplexed qRT‐PCR, demonstrating the ability to monitor molecular signature through treatment. The presented MelanoBean and the comprehensive approach will empower prognostic value of CTCs in melanoma in much larger cohort studies.